On Nov. 20, 2019. Bristol-Myers Squibb announced it had completed its acquisition of Celgene. On Jun. 29, 2015, Celgene and Juno Therapeutics announced a global collaboration for the development and commercialization of immunotherapies.

Celgene paid Juno $150 million in upfront fees, and purchased 9.1 million or $846.3 million of newly issued shares, in exchange for certain options to market Junoﾒs experimental immunotherapy treatments. Celgene was paid $93 per share, double Junoﾒs closing price of $46.30 the following Monday.